재택 만성질환 바이오마커 검사 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 기술별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

At-home Chronic Disease Biomarker Testing Market Summary

The global at-home chronic disease biomarker testing market size was estimated at USD 5.04 billion in 2025 and is projected to reach USD 18.68 billion by 2033, growing at a CAGR of 17.79% from 2026 to 2033. This growth is driven by the rising prevalence of chronic diseases, an increasing emphasis on preventive and personalized healthcare, and the rapid adoption of decentralized diagnostic solutions.

In addition, ongoing advancements in wearable technologies and digital biomarkers are further accelerating market demand. For instance, a 2023 study developed a microfluidics-based POCT platform integrated with an oxygen-sensitive membrane and smartphone detection for simultaneous measurement of multiple chronic disease biomarkers. The system demonstrated clinical-grade sensitivity, with results consistent with commercial laboratory kits.

The growth of the at-home chronic disease biomarker testing industry is driven by the rising prevalence of chronic diseases. Chronic conditions require continuous monitoring, creating a strong demand for accessible diagnostic solutions that patients can use at home. For instance, according to the World Health Organization (WHO), chronic diseases account for the majority of global deaths, and premature mortality from these conditions continues to rise due to population growth and aging. Globally, more than 830 million were living with diabetes in the year 2022, a number that has more than doubled over the past 30 years, reflecting the rapid expansion of chronic diseases across both developed and developing regions. The economic burden of chronic diseases further fuels demand for home-based testing, as these conditions require long-term treatment, frequent hospital visits, and ongoing diagnostic monitoring, all of which increase healthcare costs. Home-based biomarker testing enables early detection, continuous monitoring, and better disease management, helping reduce hospitalizations and overall expenses. In India, programs such as the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular diseases (lipids, CRP), and Stroke (NPCDCS) and investments in digital health infrastructure are further supporting the adoption of at-home testing solutions, making them a practical and cost-effective alternative to traditional healthcare delivery models.

The growing emphasis on preventive and personalized healthcare is a major factor driving the expansion of the market. Healthcare is shifting from a reactive, treatment-focused approach to a proactive model that prioritizes early detection, risk assessment, and individualized care. Preventive healthcare encourages regular monitoring of key biomarkers, enabling patients and healthcare providers to identify potential health issues before they progress to severe conditions. Personalized healthcare further enhances this trend by tailoring treatment and monitoring plans to an individual's unique physiological, genetic, and lifestyle profile. Recent initiatives, including digital health programs and wearable device integration, support continuous health monitoring and data-driven personalized care. For instance, according to a recent article, in 2025, remote patient monitoring platforms will provide actionable insights from home-based biomarker data, empowering both patients and clinicians. This combination of preventive and personalized strategies increases patient engagement, reduces complications, and lowers healthcare costs, thereby accelerating the adoption of at-home biomarker testing solutions and significantly expanding the market.

The rapid adoption of decentralized diagnostic solutions is a key driver accelerating the growth of the market. Decentralized diagnostics shift healthcare delivery from hospitals and laboratories directly to patients' homes, enabling convenient, timely, and continuous monitoring of chronic conditions. This approach reduces dependency on centralized healthcare facilities, which often face capacity constraints, long waiting times, and accessibility challenges, particularly in rural or underserved areas. At-home biomarker testing kits and remote monitoring devices allow patients to measure critical health parameters such as glucose levels, blood pressure, heart rate, and respiratory function without visiting a clinic, making disease management more efficient and patient-centric. The trend is further reinforced by advancements in digital health platforms and telemedicine, which integrate test results into real-time monitoring systems, enabling healthcare providers to track patient health remotely and adjust treatment plans promptly. Government initiatives and private investments are supporting the expansion of decentralized healthcare infrastructure, making at-home testing solutions more reliable, secure, and widely available. By improving accessibility, convenience, and care efficiency, decentralized diagnostic solutions are driving greater adoption of home-based biomarker testing, reducing healthcare costs, and enabling proactive management of chronic diseases, ultimately fueling sustained market growth.

Ongoing advancements in wearable technologies and digital biomarkers are expanding the at home chronic disease biomarker testing industry by enabling continuous, real time health monitoring outside clinical settings. Wearable biosensorssuch as smartwatches and patchesnow collect physiological data, including ECG, heart rate, and interstitial glucose, that can be translated into actionable digital biomarkers for chronic disease management. For Instance, the FDA has authorized multiple sensor based devices for at home use, including Dexcom's G7 Continuous Glucose Monitoring System and Apple's Hypertension Notification Feature, underscoring regulatory support for clinical grade wearables that empower patients to track health indicators at home. These technologies support early detection, personalized care, and remote clinician engagement, driving broader adoption of at home testing.

Global At-home Chronic Disease Biomarker Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the at-home chronic disease biomarker testing market report based on product, application, technology, distribution channel, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Test Kits/Devices
• Consumables & Reagents
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Diabetes
• Cardiovascular diseases (lipids, CRP)
• Cardiovascular diseases (tumor markers)
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassays
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Lateral Flow Assays (LFA)
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Online platforms
• Retail pharmacies
• Diagnostic labs
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
  • Norway
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Technology
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. At home Chronic Disease Biomarker Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic diseases,
    • 3.2.1.2. Increasing emphasis on preventive and personalized healthcare
    • 3.2.1.3. The rapid adoption of decentralized diagnostic solutions,
    • 3.2.1.4. Ongoing advancements in wearable technologies and digital biomarkers
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory challenges and accuracy concerns
    • 3.2.2.2. Limited awareness, cost, and accessibility
• 3.3. At home Chronic Disease Biomarker Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. At home Chronic Disease Biomarker Testing Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. At home Chronic Disease Biomarker Testing Market: Product Movement Analysis
• 4.3. At home Chronic Disease Biomarker Testing Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Test Kits/Devices
  • 4.5.1. Test Kits/Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Consumables & Reagents
  • 4.6.1. Consumables & Reagents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. At home Chronic Disease Biomarker Testing Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. At home Chronic Disease Biomarker Testing Market: Application Movement Analysis
• 5.3. At home Chronic Disease Biomarker Testing Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Diabetes
  • 5.5.1. Diabetes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Cardiovascular diseases (lipids, CRP)
  • 5.6.1. Cardiovascular diseases (lipids, CRP) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Cardiovascular diseases (tumor markers)
  • 5.7.1. Cardiovascular diseases (tumor markers) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. At home Chronic Disease Biomarker Testing Market: Technology Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. At home Chronic Disease Biomarker Testing Market: Technology Movement Analysis
• 6.3. At home Chronic Disease Biomarker Testing Market by Technology Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Immunoassays
  • 6.5.1. Immunoassays Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Polymerase Chain Reaction (PCR)
  • 6.6.1. Polymerase Chain Reaction (PCR) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Next-Generation Sequencing (NGS)
  • 6.7.1. Next-Generation Sequencing (NGS) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Lateral Flow Assays (LFA)
  • 6.8.1. Lateral Flow Assays (LFA) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. At home Chronic Disease Biomarker Testing Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. At home Chronic Disease Biomarker Testing Market: Distribution Channel Movement Analysis
• 7.3. At home Chronic Disease Biomarker Testing Market by Distribution Channel Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Online platforms (D2C, e-commerce)
  • 7.5.1. Online platforms (D2C, e-commerce) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Retail pharmacies
  • 7.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Diagnostic Labs (mail-in kits)
  • 7.7.1. Diagnostic Labs (mail-in kits) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. At home Chronic Disease Biomarker Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.9. Rest of Europe
    • 8.4.9.1. Key country dynamics
    • 8.4.9.2. Regulatory framework/ reimbursement structure
    • 8.4.9.3. Competitive scenario
    • 8.4.9.4. Rest of Europe market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Rest of Asia Pacific
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Rest of Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. Rest of Latin America
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Rest of Latin America market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. Rest of MEA
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Rest of MEA market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2025
• 9.4. Key Company Profiles
  • 9.4.1. Everlywell
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. SiPhox, Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. PrivaPath Diagnostics
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Thorne
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Quest Diagnostics
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Labcorp
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Thermo Fisher Scientific Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. 23andMe
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Segterra, Inc. (InsideTracker)
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. AMR Labs SA
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Hims & Hers Health, Inc.
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. niahealth
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. FutureWell
    • 9.4.13.1. Company overview
    • 9.4.13.2. Financial performance
    • 9.4.13.3. Product benchmarking
    • 9.4.13.4. Strategic initiatives